Scenic Biotech

📍 Amsterdam, Netherlands🗓 Founded 2017👥 38 employees💰 Last funded Jan 2025
Biotechnology Research🌐 scenicbiotech.com
Website LinkedIn
Scenic Biotech is advancing modifier therapy, a radical new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance health by acting on another gene that can improve or, in some cases, even bypass the disease impact, leading to a therapeutic effect. Our robust pipeline for neurometabolic diseases, derived from our proprietary Cell-Seq platform, includes small-molecule programs that are wholly owned. In addition, our platform is leveraged through strategic collaborations with multinational pharmaceutical leaders. By unlocking new pathways in the genome, Scenic Biotech is developing a range of modifier therapies to help patients.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
Netherlands
1
Frequently asked questions
Who invested in Scenic Biotech?
Scenic Biotech has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did Scenic Biotech last raise funding?
The most recent investment in Scenic Biotech recorded on gritt.io was in January 2025.
When was Scenic Biotech founded?
Scenic Biotech was founded in 2017.
What industry is Scenic Biotech in?
Scenic Biotech operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Scenic Biotech based?
Scenic Biotech is headquartered in Amsterdam, Netherlands.